Elanco Animal Health layoffs, on the record
Every job cut, severance charge and restructuring Elanco Animal Health reported in its annual reports, 2023 to 2025, quoted from the filings.
Headcount, as reported
| Annual report | Employees | As of |
|---|---|---|
| 10-K for 2023 | approximately 9,300 full time employees and approximately 500 fixed-duration employees | December 31, 2023 |
| 10-K for 2024 | approximately 9,000 full time employees and approximately 450 fixed-duration employees | As of December 31, 2024 |
| 10-K for 2025 | approximately 9,400 full time employees and approximately 500 fixed-duration employees | As of December 31, 2025 |
Job cuts, severance and restructuring
Our summaryBoard authorized a restructuring plan to improve operational efficiencies and realign the organization, eliminating about 420 personnel globally.
Word for word“The restructuring plan will result in the elimination of approximately 420 personnel across our global organization.” 10-K for 2023
Our summaryCompany conducted restructuring programs after the Bayer Animal Health acquisition that eliminated positions across several countries.
Word for word“For example, related to the acquisition and subsequent integration of Bayer Animal Health, we conducted restructuring programs which included the elimination of positions across several countries, primarily in sales and marketing, R&D, manufacturing and quality, and back-office support.” 10-K for 2023
Our summaryCompany recorded asset impairment, restructuring and other special charges in 2023, which decreased from 2022 mainly due to lower impairment charges and integration costs.
Word for word“Asset impairment, restructuring and other special charges decreased $56 million in 2023 compared to 2022, primarily due to lower impairment charges and costs associated with the implementation of new systems, programs and processes resulting from the integration of Bayer Animal Health.” 10-K for 2023
Our summaryThe Board of Directors authorized a restructuring plan to improve operational efficiencies and align the organizational structure with business needs, including shifting international resources from farm animal to pet health.
Word for word“In February 2024, our Board of Directors authorized a restructuring plan (the restructuring plan) to improve operational efficiencies and better align our organizational structure with current business needs, top strategic priorities and key growth opportunities.” 10-K for 2024
Our summaryThe company incurred charges associated with the restructuring plan, the majority of which related to cash-based severance costs.
Word for word“We incurred $44 million of charges associated with the restructuring plan in 2024, the majority relating to cash-based severance costs.” 10-K for 2024
Our summaryThe company's board approved the 2025 Restructuring Plan, which cuts about 300 jobs worldwide and moves another 300 positions to growth areas or lower-cost locations; it also closes two facilities and brought $155 million of charges in 2025.
Word for word“In total, the 2025 Restructuring Plan is expected to result in a global headcount reduction of approximately 300 employees, with an additional approximately 300 employees whose positions will be replaced with positions in growth areas or in lower-cost geographies.” 10-K for 2025
Our summaryThe company recorded 2025 Restructuring Plan charges of $155 million, mostly severance costs plus non-cash impairments on two facilities, and expects more charges in 2026.
Word for word“In 2025, we incurred $155 million of charges associated with the 2025 Restructuring Plan, of which $116 million related to expected cash-based severance costs and $39 million related primarily to non-cash impairment charges associated with our animal studies R&D facilities in Monheim, Germany, and our manufacturing facility in Kansas City, Kansas.” 10-K for 2025
Our summaryThe company expects to close its Kansas City manufacturing facility under the 2025 Restructuring Plan.
Word for word“As part of the 2025 Restructuring Plan, we anticipate closing our Kansas City manufacturing facility by the end of 2026.” 10-K for 2025
Our summaryThe company authorized the 2024 Restructuring Plan to shift international resources from farm animal to pet health and improve efficiency, which cost $44 million in 2024.
Word for word“Additionally, in February 2024 our Board of Directors authorized a separate restructuring plan (the 2024 Restructuring Plan) to improve operational efficiencies and better align our organizational structure with business needs, top strategic priorities and key growth opportunities.” 10-K for 2025
| Fiscal year ended | Severance costs | Restructuring charges | Cash paid for restructuring |
|---|---|---|---|
| 2016-12-31 | $42.1 million | — | — |
| 2017-12-31 | $162 million | $193.8 million | $151.4 million |
| 2018-12-31 | $15.5 million | $27.2 million | $48.9 million |
| 2019-12-31 | $8 million | $19.3 million | $31.7 million |
| 2020-12-31 | $155 million | $157 million | $44 million |
| 2021-12-31 | $110 million | $110 million | $114 million |
| 2022-12-31 | −$9 million | −$7 million | — |
| 2023-12-31 | — | $0 | — |
| 2024-12-31 | — | $44 million | $32 million |
| 2025-12-31 | — | $156 million | $10 million |
Elanco Animal Health filed 7 restructuring notices (Form 8-K, Item 2.05) since 2016. This page shows what the company reported to the SEC, not news reports or state layoff notices.
Read from Elanco Animal Health’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-24. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.